Keypoints:
• The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate.
• The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment.
• Key findings from the LUMINOSITY trial, including response rates and study design.
• The importance of C-met testing in clinical practice.
• Management of side effects associated with telisotuzumab, particularly peripheral neuropathy.
In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain had the pleasure of welcoming Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial.
We began by exploring the crowded landscape of metastatic NSCLC treatments, emphasizing the importance of next-generation sequencing (NGS) for identifying actionable mutations. Dr. Camidge explained the mechanism of action of telisotuzumab, an antibody-drug conjugate targeting MET protein expression, which is relevant in about 12-13% of non-squamous, EGFR wild-type NSCLC cases.
Dr. Camidge provided insights into the prevalence of C-met overexpression, its role as both a primary expression and a potential resistance mechanism, and the importance of testing for it alongside PD-L1. We discussed the LUMINOSITY trial's design, focusing on the response rates observed in different cohorts, particularly the MET high group, which achieved a 54% response rate.
As we delved deeper, we examined the implications of C-met overexpression in treatment decisions, especially in the first line, and how it interacts with other mutations like KRAS and ALK. Dr. Camidge also highlighted the side effects associated with telisotuzumab, particularly peripheral neuropathy, and shared clinical pearls for managing these toxicities effectively.
In closing, we recapped the key points of our discussion, emphasizing the significance of C-met testing in non-squamous NSCLC and the potential of telisotuzumab as a new treatment option. We look forward to future confirmatory data that will help solidify its role in clinical practice.
Listen Podcast on Your Favourite Platform
